The Evidentiary Standard That Is Reshaping Scientific Claims
As regulatory bodies and market gatekeepers apply greater scrutiny to the evidence behind product claims, the gap between what businesses assert and what science can genuinely support has become a source of commercial and legal risk.
This article examines the evolving evidentiary standards applied to scientific claims in regulated and commercial contexts — exploring what constitutes defensible evidence, how organisations can identify and close their evidentiary gaps, and why scientific credibility has become a prerequisite for market access, not merely a regulatory compliance obligation.
For most of the past two decades, the practical standard for a scientific claim in consumer health, nutrition, and life science markets was relatively permissive. A plausible mechanism, a handful of supporting studies, and a carefully worded label were often sufficient to bring a product to market. That era is ending — and the organisations that have not yet adjusted to the new evidentiary expectations are increasingly discovering the consequences.
The shift has not been driven by a single regulatory event. It has emerged gradually — through the accumulating weight of enforcement actions, retailer compliance programmes, investor due diligence processes, and litigation — until the expectation of documented, structured, peer-reviewed scientific support has moved from an aspiration to a threshold requirement.
What the Evidentiary Standard Actually Requires
The phrase “scientific evidence” is used so broadly in commercial and regulatory contexts that it has become almost meaningless in isolation. A single in vitro study and a systematic review of randomised controlled trials are both, technically, “scientific evidence.” The distinction between them — in terms of what they can and cannot establish — is precisely what regulators, retailers, and opposing experts will examine.
Evidentiary quality is not simply a question of volume. An organisation that cites fifty low-quality studies is not better positioned than one that cites five methodologically rigorous ones. The structure of the evidence — its hierarchy, its relevance, and its coherence — matters more than its quantity.
The elements of a defensible evidentiary position include: a defined and relevant claim; a systematic review of the literature that is both comprehensive and reproducible; an evidence hierarchy that distinguishes clinical from mechanistic data; and a clear articulation of what the evidence supports and what it does not.
The Evidence Hierarchy
Different categories of scientific evidence carry different weight in regulatory and evidentiary assessments. Understanding this hierarchy is not a technical nicety — it determines whether a scientific position is defensible or merely plausible.
| Evidence Type | Typical Weight | Common Limitation |
|---|---|---|
| Systematic review / Meta-analysis | Highest | Dependent on quality of included studies |
| Randomised controlled trial (RCT) | High | Generalisability of study population |
| Cohort / Epidemiological study | Moderate | Confounding; association not causation |
| Mechanistic / In vitro data | Supportive | Does not establish clinical effect in humans |
| Expert opinion / Case reports | Low | Susceptible to bias; lowest evidentiary value |
Where Organisations Most Commonly Fail
In FSC’s experience advising commercial and institutional clients, evidentiary failures rarely stem from deliberate misrepresentation. They stem from a misunderstanding of what the evidence actually establishes — and from the absence of any structured process for evaluating it.
- Relying on mechanistic evidence to support clinical claims
- Using studies conducted on different formulations, doses, or populations
- Citing literature that has since been superseded or retracted
- Failing to distinguish between statistical significance and clinical relevance
- Building a scientific dossier without a structured evidence hierarchy
“The question is never whether evidence exists. It is whether the evidence that exists is sufficient, relevant, and structured to the standard that will be applied when it is examined.”
Building a Defensible Scientific Position
The organisations that navigate this environment most successfully share a common characteristic: they treat scientific evidence as a managed asset, not an afterthought. They identify their evidentiary requirements before making claims, not after. They commission systematic reviews rather than literature searches. And they engage independent scientific expertise to stress-test their positions before those positions are tested externally.
A 2023 analysis of FTC enforcement actions in the health and wellness sector found that the most common point of regulatory failure was not the absence of evidence, but the mismatch between the claim made and the evidence cited in its support. Organisations were citing real studies — they were simply using them to support claims the studies were not designed to establish.
Source: Federal Trade Commission, Health Products Compliance Guidance, 2022.
- Define the specific claim with precision before seeking evidence to support it
- Conduct a systematic literature review — not a selective citation exercise
- Apply a structured evidence hierarchy to assess the quality of each source
- Identify and document the limits of what the evidence supports
- Engage independent scientific review to stress-test the position
- Maintain and update the evidentiary dossier as the science evolves
The Independent Scientific Perspective
One dimension of this challenge that is frequently underestimated is the value of independence. An organisation’s internal team — however scientifically capable — has an inherent interest in the strength of the scientific position. An external scientific consultant, engaged without instruction as to preferred outcome, provides something qualitatively different: an honest assessment of what the evidence supports, including its weaknesses and its limits.
That independence is not a limitation on the value of external scientific consulting. It is the source of its value — precisely because it is the same independence that regulatory reviewers, opposing counsel, and institutional gatekeepers will apply when they evaluate the position.
- Federal Trade Commission. Health Products Compliance Guidance. FTC, 2022.
- Sackett DL et al. Evidence-based medicine: what it is and what it isn’t. BMJ. 1996;312:71.
- Guyatt GH et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924.
- European Food Safety Authority. General guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 2011.
Five things this article establishes
- 1 Evidentiary standards for scientific claims have materially increased across regulatory, retail, and legal contexts — and organisations that have not adjusted face growing commercial and legal risk.
- 2 The quality and structure of scientific evidence matters more than its volume — a small number of rigorous studies is more defensible than a large number of weak ones.
- 3 Most evidentiary failures stem from a mismatch between the claim made and what the cited evidence actually establishes — not from a deliberate absence of evidence.
- 4 A defensible scientific position requires a defined claim, a systematic literature review, an applied evidence hierarchy, and documented acknowledgment of evidentiary limits.
- 5 Independent scientific review adds value precisely because of its independence — providing the same objective standard that external reviewers will apply.
Why this matters beyond compliance
The shift in evidentiary standards is not simply a regulatory phenomenon. It reflects a deeper change in how scientific credibility functions in commercial and institutional contexts. Scientific claims that cannot withstand structured scrutiny are not merely a compliance risk — they are a reputational risk, a litigation risk, and, increasingly, a commercial risk as gatekeepers at every level of the supply chain raise their evidentiary expectations.
FSC’s position is that the organisations best positioned in this environment are those that invest in genuine scientific rigour — not as a response to external pressure, but as a strategic foundation. The infrastructure required to produce a defensible scientific position is the same infrastructure required to make better scientific decisions internally. The investment compounds.
Explore our scientific services
Browse the full range of FSC’s independent scientific consulting services and research resources.